Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver

Journal of Inflammation

Volumn 2, Issue , 2005, Pages

  Smolinski, Alexa T ^a,b   Pestka, James J ^a,b,c  

^a Michigan State University   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; HERBACEOUS AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PARTHENOLIDE; TANACETUM PARTHENIUM EXTRACT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE INDUCTION; LIVER; LIVER LEVEL; MOUSE; NONHUMAN; SPLEEN; TISSUE LEVEL;

ANIMALIA; MURINAE; TANACETUM PARTHENIUM;

EID: 23944514626     PISSN: 14769255     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-9255-2-6     Document Type: Article

References (30)

1. Groenewegen WA, Heptinstall S: A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J Pharm Pharmacol 1990, 42:553-557.
2. Schinella GR, Giner RM, Recio MC, Mordujovich dB, Rios JL, Manez S: Anti-inflammatory effects of South American Tanacetum vulgare. J Pharm Pharmacol 1998, 50:1069-1074.
3. Jain NK, Kulkarni SK: Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. J Ethnopharmacol 1999, 68:251-259.
4. Sumner H, Salan U, Knight DW, Hoult JR: Inhibition of 5-lipoxygenase and cyclooxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992, 43:2313-2320.
5. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W: Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996, 226:810-8.
6. O'Neill LA, Barrett ML, Lewis GP: Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: a cytotoxic effect. Br J Clin Pharmacol 1987, 23:81-83.
7. Pugh WJ, Sambo K: Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 1988, 40:743-745.
8. Uchi H, Arrighi JF, Aubry JP, Furue M, Hauser C: The sesquiterpene lactone parthenolide inhibits LPS- but not TNF-alphainduced maturation of human monocyte-derived dendritic cells by inhibition of the p38 mitogen-activated protein kinase pathway. J Allergy Clin Immunol 2002, 110:269-276.
9. Hehner SP, Hofmann TG, Droge W, Schmitz ML: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 1999, 163:5617-23.
10. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, et al.: Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 1998, 273:1288-1297.
11. Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M: Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 1997, 402:85-90.
12. Rungeler P, Castro V, Mora G, Goren N, Vichnewski W, Pahl HL: Inhibition of transcription factor NF-kappaB by sesquiterpene lactones: a proposed molecular mechanism of action. Bioorg Med Chem 1999, 7:2343-2352.
13. 1 (ginseng) and parthenolide (feverfew). Food Chem Toxicol 2005, 41:1381-1390.
14. Kang BY, Chung SW, Kim TS: Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by parthenolide, a predominant sesquiterpene lactone in Tanacetum parthenium: involvement of nuclear factor-kappaB. Immunol Lett 2001, 77:159-163.
15. Mazor RL, Menendez IY, Ryan MA, Fiedler MA, Wong HR: Sesquiterpene lactones are potent inhibitors of interleukin 8 gene expression in cultured human respiratory epithelium. Cytokine 2000, 12:239-45.
16. Howard HL, McLaughlin-Taylor E, Hill RL: The effect of mouse euthanasia technique on subsequent lymphocyte proliferation and cell mediated lympholysis assays. Lab Anim Sci 1990, 40:510-514.
17. Schuurman H, Krajnc-Franken M, Kuper C, van Loveren H, Vos J: Immune System. In Fundamentals of Toxicologic Pathology Edited by: Haschek W, Rousseaux C. San Diego: Academic Press; 1998:233-272.
18. Popp J, Cattely R: Hepatobiliary System. In Fundamentals of Toxicologic Pathology Edited by: Haschek W, Rousseaux C. San Diego: Academic Press; 1998:127-151.
19. Lau AH, Thomson AW: Dendritic cells and immune regulation in the liver. Gut 2003, 52:307-314.
20. Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A, et al.: APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol 2002, 169:7111-7118.
21. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
22. Mercurio F, Manning AM: Multiple signals converging on NF-kappaB. Curr Opin Cell Biol 1999, 11:226-32.
23. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-83.
24. Baeuerle PA, Baichwal VR: NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997, 65:111-137.
25. Tak PP, Firestein GS: NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001, 107:7-11.
26. Poli V: The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem 1998, 273:29279-29282.
27. Yokoo T, Kitamura M: Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol 1996, 270:F123-F130.
28. Wardlaw SA, Zhang N, Belinsky SA: Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumorderived cell lines by CCAAT/enhancer-binding protein and activating transcription factor/cAMP response elementbinding protein. Mol Pharmacol 2002, 62:326-333.
29. Wedel A, Ziegler-Heitbrock HW: The C/EBP family of transcription factors. Immunobiology 1995, 193:171-85.
30. Zhou HR, Islam Z, Pestka JJ: Kinetics of lipopolysaccharideinduced transcription factor activation/inactivation and relation to proinflammatory gene expression in the murine spleen. Toxicol Appl Pharmacol 2003, 187:147-161.